The HealthPod: Recent Episodes
Marvin Pathrose
Welcome to The Healthpod. Every week ( or close to it) I'll try to tackle issues of clinical practice, new therapies, finances, and insurance in relation to the healthcare world. Take better care of yourself and patients by staying informed! Please reach out if there are any specific topics that you would like covered or find interesting! Cover art photo provided by freestocks.org on Unsplash: https://unsplash.com/@freestocks
This episode we revisit another psychedilic MDMA. Its crazy how there are people that abhorrently deny the benefit of these "recreational" drugs. I am giving some brief data on how MDMA can prove useful.'
MAPS clinical trial- http://bit.ly/2FNZP78
Current Perspective on MDMA-Assisted Psychotherapy for Posttraumatic Stress Disorder -http://bit.ly/2I4Q6eb
Move over anti-depressents there's a new MOA in town. This episode details a new intranasal ketamine produce by Janssen pharmaceuticals.
This is a brief look at the data we have so far. Enjoy!
SPRAVATO- http://bit.ly/2URxZfv
Pharmacology of Ketamine study- http://bit.ly/2HyzETT
This episode delves into a drug that most of us need on a daily basis. CAFFEINE. This wonder molecule affects so many of our body's processes.
If your curious how it works and what makes it affect you so profoundly, give this episode a listen.
Enjoy!
Genetics of caffeine consumption and responses to caffeine- http://bit.ly/2XJDSwY
This episode revisits why statins and if they are as beneficial as currently believed. There are many nuances about statins and confusion. Hopefully this episode clears things up!
Saturated fat is not the major issue -http://bit.ly/2GxkgH9
Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above - http://bit.ly/2T9e5P8
Interpretation of the evidence for the efficacy and safety of statin therapy - http://bit.ly/2T9Sbvv
Long-term moderately elevated LDL-cholesterol and blood pressure and risk of coronary heart disease - http://bit.ly/2twk7Le
Debate on LDL Role in Heart Disease Reignited Out of the Blue -https://wb.md/2tsnUJw
European Atherosclerotic Society Statement - https://wb.md/2tufWzF
AHA safety statement- http://bit.ly/2GMIe0l
Benefits vs. Harm of statins- http://bit.ly/2NdzPE7
This episode is going to go over what I found related the most to in the state of the union address to healthcare. There were many outlandish claims but this address could have been way worse than it turned out.
https://wb.md/2GtrTgR
This episode is a brief synopsis on trends in the Flu season so far and a new FDA generic approval of a long standing respiratory inhaler.
Influenza upswing- https://wb.md/2UJFnJm
Advair generic- https://wb.md/2TyoD7r
FDA statement on ARBs recalls- http://bit.ly/2DVNxZA
Ibuprofen Recall by Tris Pharm Inc.- http://bit.ly/2RKKzLa
The various lots recalled include:
Lot 4718 — sold in a .5 oz. bottle with an expiration date of Dec. 2019 — and lot 00717006A — sold in a 1 oz. bottle with an expiration date of Feb. 2019 — were manufactured under the "CVS Health" label, according to the release. Lot 00717005A — sold in a 1 oz. bottle with an expiration date of Feb. 2019 — was manufactured under the "Equate" label for Walmart.
This episode is a brief update on the opioid epidemic.
A Perspective Regarding the Current State of the Opioid Epidemic. | Psychiatry | JAMA Network Open | JAMA Network- http://bit.ly/2WEZaLw
FDA announcemet- http://bit.ly/2DQh8TW
This episode is the introduction into my new format of shorter and more digestible episodes.
N.Y.C healthcare- https://wb.md/2UzRA
Wyoming patient infected- https://wb.md/2GhTaTw
- Clot permeability and Thrombolytic risk: https://wb.md/2CVGv6t What is clot permeability: http://bit.ly/2CVFD1H 2. Andexxa Commercial Production Approval: https://wb.md/2CThfOe 3. Flu data: https://wb.md/2Vx0Q9s CDC Reports: http://bit.ly/2CVaTO8 4. Sartan Saga: https://wb.md/2FfgukM Aurobindo: http://bit.ly/2GXqjpu Torrent: http://bit.ly/2saUsqY 5. Mediterranean vs. Dash Diet in U.S Rankings: https://wb.md/2Ca1D7d 6. Celgene acquisition: https://read.bi/2AyHt6S
What better way to start the year then with staying on top of healthcare. This episode covers the new flu guidelines, a novel mechanism in schizophrenia, and Newly found risk of basal insulin and sulfonylureas. IDSA influenza guidelines- http://bit.ly/2QYLM5Q Novel schizophrenia molecule SEP-363856 - http://bit.ly/2QaiFr3 What is a PANSS test- http://bit.ly/2GOhCOa New emergent risks with Basal insulin and Sulfonylureas- http://bit.ly/2QXF1kG New flu medication Xofluza (baloxivir marboxil) - http://bit.ly/2EWt9s5
This week I review what's going on with the Valsartan recall, VTE risk reduction in prophylaxis, Increased death in children with antipsychotics, new cannabis therapy, and new use for modafinil. 1. Valsartan recall https://wb.md/2EBred0 FDA warning letter: http://bit.ly/2STOdTF 2. Apixiban Reduction of VTE risk in Cancer Patients: https://wb.md/2rKavvI AVERT Study: http://bit.ly/2CkGGYS 3. Antipyschotics linked to increased mortality in young patients https://wb.md/2CkRg1S Full study: http://bit.ly/2BBV3Xd 4. Cannabis use disorder https://wb.md/2LoZ9q7 Full study for purchase: http://bit.ly/2S8lyub 5. Modafinil for stimulant abuse https://www.medscape.com/viewarticle/906587 Any questions or ideas please contact me at healthpodmp@gmail.com
This episode reviews what has happened in the previous week in healthcare. For more information on the topics discussed please see the links provided. Valsartan recall: https://www.medscape.com/viewarticle/906158 FDA list of recent Mylan lots: https://www.fda.gov/Safety/Recalls/ucm627647.htm?utm_campaign=FDA%20updates%20on%20angiotensin%20II%20receptor%20blocker%20(ARB)%20recalls:%20Mylan%20expands&utm_medium=email&utm_source=Eloqua This Table will go over "NDMA" levels not NDEA as mentioned. NDEA results will be released at a later date: https://www.fda.gov/Drugs/DrugSafety/ucm622717.htm Medications other than statins: https://www.medscape.com/viewarticle/905377 Study on the mediteranian diet: https://www.medscape.com/viewarticle/898110 Information on PCSK9 (evolocumab) inhibitor: https://reference.medscape.com/drug/repatha-evolocumab-1000002 Zetia (ezetimibe) information: https://reference.medscape.com/drug/zetia-ezetimibe-342454 Dextenza: https://www.medscape.com/viewarticle/905896 https://reference.medscape.com/drug/dextenza-dexamethasone-ophthalmic-insert-1000162 Niacin Fibrates: Atezolizumab new indication: https://www.medscape.com/viewarticle/906252 Bladder cancer information: https://emedicine.medscape.com/article/438262-overview Bevacizumab: https://reference.medscape.com/drug/avastin-bevacizumab-https://reference.medscape.com/drug/avastin-bevacizumab-342257 Paclitaxel: https://reference.medscape.com/drug/taxol-paclitaxel-342187 Carboplatnin: https://reference.medscape.com/drug/paraplatin-carboplatin-342107 IMPOWER150 Trial info: https://www.esmo.org/Oncology-News/ASCO-2018-First-Line-Atezolizumab-Improves-Survival-in-Advanced-NSCLC
Again Thanks for listening! My email in healthpodmp@gmail.com
Ever wonder why take a statin? Especially if your young and beautiful other health problems. Take a listen to this podcast and learn why.
This episode goes into some more valsartan recalls, AML drugs and AHA HTN guidelines controversy, and lipid guidelines
- Valsartan recall 2. Travelers diarrhea 3. AML 4. Supplement contamination 5. Chicago shooting